INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation

NASDAQ:INDV • US45579U1097

Current stock price

32.7 USD
+0.39 (+1.21%)
Last:

This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. INDV Profitability Analysis

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • INDV had a positive operating cash flow in the past year.
  • In multiple years INDV reported negative net income over the last 5 years.
  • In multiple years INDV reported negative operating cash flow during the last 5 years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • The Return On Assets of INDV (8.62%) is better than 89.58% of its industry peers.
  • INDV has a Return On Invested Capital of 50.62%. This is amongst the best in the industry. INDV outperforms 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for INDV is significantly above the industry average of 13.06%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 10.34%, INDV belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
  • INDV's Profit Margin has declined in the last couple of years.
  • The Operating Margin of INDV (24.49%) is better than 92.19% of its industry peers.
  • INDV's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of INDV (85.51%) is better than 88.54% of its industry peers.
  • In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INDV Health Analysis

2.1 Basic Checks

  • INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • INDV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.62. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of INDV (2.62) is better than 66.67% of its industry peers.
  • INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
  • INDV has a better Debt to FCF ratio (2.68) than 92.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.62
ROIC/WACC5.39
WACC9.4%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a worse Current ratio (0.96) than 85.42% of its industry peers.
  • A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
  • The Quick ratio of INDV (0.79) is worse than 82.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. INDV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 459.09% over the past year.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.07% on average over the next years.
  • The Revenue is expected to grow by 0.79% on average over the next years.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. INDV Valuation Analysis

4.1 Price/Earnings Ratio

  • INDV is valuated correctly with a Price/Earnings ratio of 13.29.
  • Based on the Price/Earnings ratio, INDV is valued cheaper than 87.50% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.91. INDV is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 10.61 indicates a reasonable valuation of INDV.
  • Based on the Price/Forward Earnings ratio, INDV is valued cheaper than 87.50% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.68, INDV is valued rather cheaply.
Industry RankSector Rank
PE 13.29
Fwd PE 10.61
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 84.90% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, INDV is valued cheaply inside the industry as 81.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.08
EV/EBITDA 12.44
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INDV has a very decent profitability rating, which may justify a higher PE ratio.
  • INDV's earnings are expected to grow with 13.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.53
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INDV Dividend Analysis

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDV Fundamentals: All Metrics, Ratios and Statistics

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (4/10/2026, 10:25:23 AM)

32.7

+0.39 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-23
Inst Owners86.43%
Inst Owner Change0%
Ins Owners3.62%
Ins Owner Change39.75%
Market Cap4.09B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target47.79 (46.15%)
Short Float %10.15%
Short Ratio4.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.82%
PT rev (3m)23.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 13.29
Fwd PE 10.61
P/S 3.47
P/FCF 34.08
P/OCF 22.72
P/B N/A
P/tB N/A
EV/EBITDA 12.44
EPS(TTM)2.46
EY7.52%
EPS(NY)3.08
Fwd EY9.42%
FCF(TTM)0.96
FCFY2.93%
OCF(TTM)1.44
OCFY4.4%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.53
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.62
F-Score8
WACC9.4%
ROIC/WACC5.39
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1051.87%
EBIT Next 3Y148.64%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status for INDV stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


How profitable is INDIVIOR PHARMACEUTICALS INC (INDV) stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


Can you provide the financial health for INDV stock?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


What is the expected EPS growth for INDIVIOR PHARMACEUTICALS INC (INDV) stock?

The Earnings per Share (EPS) of INDIVIOR PHARMACEUTICALS INC (INDV) is expected to grow by 25.28% in the next year.